GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Zylox-Tonbridge Medical Technology Co Ltd (HKSE:02190) » Definitions » Tax Expense

Zylox-Tonbridge Medical Technology Co (HKSE:02190) Tax Expense : HK$0.0 Mil (TTM As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Zylox-Tonbridge Medical Technology Co Tax Expense?

Zylox-Tonbridge Medical Technology Co's tax expense for the months ended in Jun. 2024 was HK$0.0 Mil. Its tax expense for the trailing twelve months (TTM) ended in Jun. 2024 was HK$0.0 Mil.


Zylox-Tonbridge Medical Technology Co Tax Expense Historical Data

The historical data trend for Zylox-Tonbridge Medical Technology Co's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zylox-Tonbridge Medical Technology Co Tax Expense Chart

Zylox-Tonbridge Medical Technology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Tax Expense
Get a 7-Day Free Trial - - - - -

Zylox-Tonbridge Medical Technology Co Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - 0.32 -0.32 - -

Zylox-Tonbridge Medical Technology Co Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zylox-Tonbridge Medical Technology Co  (HKSE:02190) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Zylox-Tonbridge Medical Technology Co Tax Expense Related Terms

Thank you for viewing the detailed overview of Zylox-Tonbridge Medical Technology Co's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Zylox-Tonbridge Medical Technology Co Business Description

Traded in Other Exchanges
Address
270 Shuyun Road, Cangqian Street, Zylox-Tonbridge Industrial Park, Yuhang District, Zhejiang Province, Hangzhou, CHN
Zylox-Tonbridge Medical Technology Co Ltd is principally engaged in providing solutions to patients and physicians with a product portfolio covering peripheral-vascular interventional devices and neurovascular interventional devices in China and other countries. The company's main products include Thrombite Clot Retriever Device (Thrombite CRD) and Ultrafree Drug Coated PTA Balloon Catheter (Ultrafree DCB).
Executives
Wang Stephen Hui 2201 Interest of corporation controlled by you
Hang Zhou Gui Qiao Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2401 A concert party to an agreement to buy shares
Zhu Hai Tong Qiao Tou Zi Zhong Xin You Xian He Huo 2401 A concert party to an agreement to buy shares
Hang Zhou Fu Jiang Tou Zi He Huo Qi Ye You Xian He Huo 2401 A concert party to an agreement to buy shares
Zhu Hai Gui Chuang Gu Quan Tou Zi Zhong Xin You Xian He Huo 2401 A concert party to an agreement to buy shares
Hu Zhou Yu Yi Hui Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2401 A concert party to an agreement to buy shares
Wea Enterprises, Llc 2401 A concert party to an agreement to buy shares
Zhong Shengping Sam 2401 A concert party to an agreement to buy shares
Zhao Jonathon Zhong 2501 Other
Wei Na 2501 Other
Li Zheng 2501 Other
Schroders Plc 2102 Investment manager
Ourea Biotech Hk Limited 2501 Other
Highlight Medical Limited 2501 Other
Five Investment Limited 2501 Other

Zylox-Tonbridge Medical Technology Co Headlines

No Headlines